Clinical Trial Update: Safety Study of a Fluorescent Marker to Visualize Cancer Cells [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating a fluorescent marker (Tumor Paint/BLZ-100) to visualize cancer cells in skin neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Neoplasms

Drugs mentioned

• Tumor Paint (BLZ-100) (BLZ-100)

Snippet

Sponsor: Blaze Bioscience Australia Pty Ltd | Conditions: Skin Neoplasms | Phase 1 | Status: COMPLETED